Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0F7AT
|
||||
| Former ID |
DAP000479
|
||||
| Drug Name |
Cryptenamine Acetates
|
||||
| Synonyms |
Unitensen; Cryptenamine Tannates; Cryptenamine Acetates
|
||||
| Indication | Hypertension [ICD9: 401; ICD10:I10-I16] | Approved | [1] | ||
| Therapeutic Class |
Cardiovascular Agents
|
||||
| Company |
Medpointe Pharmaceuticals Medpointe Healthcare Inc
|
||||
| Formula |
C28H46O10N
|
||||
| CAS Number |
CAS 1356-18-9
|
||||
| Target and Pathway | |||||
| Target(s) | Muscarinic acetylcholine receptor M5 | Target Info | Modulator | [2] | |
| KEGG Pathway | Calcium signaling pathway | ||||
| Neuroactive ligand-receptor interaction | |||||
| Cholinergic synapse | |||||
| Regulation of actin cytoskeleton | |||||
| PANTHER Pathway | Alzheimer disease-amyloid secretase pathway | ||||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | |||||
| Reactome | Muscarinic acetylcholine receptors | ||||
| G alpha (q) signalling events | |||||
| WikiPathways | Monoamine GPCRs | ||||
| Calcium Regulation in the Cardiac Cell | |||||
| Regulation of Actin Cytoskeleton | |||||
| GPCRs, Class A Rhodopsin-like | |||||
| Gastrin-CREB signalling pathway via PKC and MAPK | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | ||||
| REF 2 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.